Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Eli Lilly
(NY:
LLY
)
1,071.64
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EST, Dec 23, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
JPMorgan Says 2027 Medicare Drug Prices Signal Up To 40% Cuts Ahead — Novo Nordisk And Teva Stand Out As Top Targets
↗
November 26, 2025
JPMorgan said the implied net impact aligns with recent commentary from Novo Nordisk, Teva and AbbVie during earnings season.
Via
Stocktwits
Topics
Economy
Government
Stock Split Watch: Is Eli Lilly Next?
↗
November 26, 2025
The stock recently reached beyond $1,000.
Via
The Motley Fool
U.S. Stocks Extend Winning Streak as Wall Street Bets on Dovish Fed Pivot
November 26, 2025
New York, NY – November 26, 2025 – U.S. stock markets are surging, with Wall Street poised to extend a remarkable winning streak as investors enthusiastically price in aggressive interest rate cuts by...
Via
MarketMinute
Topics
Artificial Intelligence
Bonds
Economy
Is AbbVie Stock Outperforming the Nasdaq?
November 26, 2025
AbbVie has outperformed the Nasdaq over the past year, and analysts are moderately optimistic about the stock’s prospects.
Via
Barchart.com
Topics
Stocks
Could AI Infrastructure Spending Be the Next Gold Rush for Investors?
↗
November 26, 2025
Companies and investors see AI as a game-changing technology.
Via
The Motley Fool
Topics
Artificial Intelligence
Did Pfizer Just Say "Checkmate" to Novo Nordisk?
↗
November 26, 2025
The weight loss drug market may approach almost $100 billion by the end of the decade.
Via
The Motley Fool
Retail Traders Crown Novo Nordisk As Long-Term Weight Loss King — Even As Eli Lilly Hits $1T And Viking Fans Tout ‘M&A Prize’
↗
November 25, 2025
Users pointed to emerging drug pipelines, GLP-1 expansion and rising M&A pressure across the sector.
Via
Stocktwits
Q3 Rundown: Organon (NYSE:OGN) Vs Other Branded Pharmaceuticals Stocks
November 25, 2025
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Organon (NYSE:OGN) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Should You Buy the Massive Dip in Novo Nordisk Stock?
November 25, 2025
Novo’s failed Alzheimer’s bet sparked a sharp selloff, leaving investors debating whether this bruising dip is a bargain or not.
Via
Barchart.com
Here's Why Novo Nordisk Stock Popped Today
↗
November 25, 2025
Good news from a GLP-1 receptor agonist clinical trial hit the market today.
Via
The Motley Fool
The Great Divide: Is the Market Offering a Dip or Signalling a Bear?
November 25, 2025
As November 25, 2025, unfolds, financial markets find themselves at a critical juncture, gripped by a pervasive debate that pits optimists against skeptics: are current market pullbacks merely a "Buy...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Stocks
Is UnitedHealth Group Stock Underperforming the Nasdaq?
November 25, 2025
Though UnitedHealth Group has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.
Via
Barchart.com
Topics
Stocks
A Trillion-Dollar Pill: Eli Lilly Broke the Healthcare Ceiling
↗
November 25, 2025
Via
MarketBeat
How Is Eli Lilly’s Stock Performance Compared to Other Pharmaceuticals?
November 25, 2025
Eli Lilly’s remarkable outperformance within the pharmaceutical sector hasn’t tempered enthusiasm, analysts are still strongly bullish on its long-term growth potential.
Via
Barchart.com
Topics
ETFs
This Healthcare Company Just Touched $1 Trillion in Market Cap. Should You Invest $1,000?
↗
November 24, 2025
The rapidly expanding market for GLP-1 drugs has added massively to Eli Lilly's market cap.
Via
The Motley Fool
Topics
Government
World Trade
Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk
↗
November 24, 2025
Novo's trial setback tests GLP-1-heavy ETFs, highlighting concentration risks while Eli Lilly's diversified pipeline offers relative resilience.
Via
Benzinga
Topics
ETFs
US Stock Market Navigates AI Euphoria and Rate Cut Hopes Amidst Mounting Volatility
November 24, 2025
The US stock market as of late November 2025 presents a nuanced landscape of resilience and apprehension. While major indices have enjoyed robust year-to-date gains, largely propelled by the relentless...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Electric Vehicles
Novo Nordisk Shares Plunge as Alzheimer's Drug Trial Fails to Meet Primary Endpoint
November 24, 2025
Copenhagen, Denmark – November 24, 2025 – Novo Nordisk's (CPH: NOVO B) stock experienced a significant and immediate downturn today, plummeting by over 10% in early trading, following the announcement...
Via
MarketMinute
Biotech Valuations Rise as New Clinical Platforms Show Progress
November 24, 2025
Via
Investor Brand Network
Biotech Valuations Rise as New Clinical Platforms Show Progress
November 24, 2025
From
BioMedWire
Via
GlobeNewswire
Novo Nordisk Dives As Ozempic Fails To Slow Alzheimer's; Lilly Falls, Biogen Jumps
↗
November 24, 2025
Eli Lilly fell while Biogen jumped.
Via
Investor's Business Daily
Eli Lilly & Co (NYSE:LLY) Presents a Compelling Case for Growth at a Reasonable Price
↗
November 24, 2025
Eli Lilly (LLY) presents strong growth at a reasonable price (GARP), with accelerating earnings and revenue supported by top-tier profitability.
Via
Chartmill
1 Spectacular Warren Buffett-Approved Index Fund That Could Turn $500 Per Month Into $1 Million
↗
November 24, 2025
Investing in an S&P 500 index fund can be a great way to build long-term wealth.
Via
The Motley Fool
Topics
ETFs
Economy
Stocks
Wall Street Rebounds—but Confidence Remains on a Short Leash
↗
November 24, 2025
After a bruising week, Wall Street regained its footing on Friday as rate-cut hopes resurfaced and fears around the AI sell-off eased, if only slightly. Solid PMI data and improving inflation...
Via
Chartmill
Topics
Artificial Intelligence
Economy
Madrigal Pharma Stock Sees Buyout Hype – Retail Predicts ‘Huge’ Deal On Liver Disease Drug Momentum
↗
November 24, 2025
Fresh analyst target hikes followed new two-year clinical data showing sustained improvements in key liver-health measures.
Via
Stocktwits
Q3 Earnings Outperformers: Merck (NYSE:MRK) And The Rest Of The Branded Pharmaceuticals Stocks
November 23, 2025
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Merck (NYSE:MRK) and the best and worst...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Billionaire Stanley Druckenmiller Dropped Nvidia, Palantir, and Eli Lilly Over the Past Year and Just Bought the 2 Cheapest Magnificent Seven Stocks.
↗
November 23, 2025
These Magnificent Seven players are well-positioned to benefit in the AI boom.
Via
The Motley Fool
Topics
Artificial Intelligence
2 Top Dividend Stocks for Growth-Oriented Investors
↗
November 23, 2025
Who says you have to choose between the two?
Via
The Motley Fool
Topics
Artificial Intelligence
Novo Nordisk Just Took a Big Swing, Slashing Its GLP-1 Drug Prices. Will It Pay Off for the Healthcare Giant?
↗
November 23, 2025
The obesity drug producer has taken some hits throughout the past year, but it is beginning to punch back.
Via
The Motley Fool
Topics
Government
2 Major Stocks Want to Dominate the GLP-1 Market. Which One Looks Like the Leader Heading Into 2026?
↗
November 22, 2025
Many other drugmakers are attempting to break this duopoly, but this may not happen anytime soon.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.